Generic Name: durvalumab
Brand Name: Imfinzi
Manufacturer: AstraZeneca Canada Inc.
Therapeutic Area: Extensive-stage small cell lung cancer
Indications: IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Manufacturer Requested Reimbursement Criteria1: As per Health Canada indication: in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Submission Type: Initial
Tumour Type: Lung
NOC Status at Filing: Post NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule1: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient/clinician input open||November 03, 2020|
|Call for patient/clinician input closed||December 24, 2020|
- Patient input submission received from Lung Cancer Canada and Lung Health Foundation
|Submission received||December 01, 2020|
|Submission accepted||December 15, 2020|
|Review initiated||December 16, 2020|
|Draft CADTH review report(s) provided to sponsor for comment||March 22, 2021|
|Deadline for sponsors comments||March 31, 2021|
|CADTH responses on draft review report(s) provided to sponsor||May 03, 2021|
|Expert committee meeting (initial)||May 14, 2021|
|Draft recommendation issued to sponsor||May 31, 2021|
|Draft recommendation posted for stakeholder feedback||-|